Transcatheter Arterial Chemoembolization for Infiltrative Hepatocellular Carcinoma: Clinical Safety and Efficacy and Factors Influencing Patient Survival.
10.3348/kjr.2014.15.4.464
- Author:
Kichang HAN
1
;
Jin Hyoung KIM
;
Hee Mang YOON
;
Eun Joung KIM
;
Dong Il GWON
;
Gi Young KO
;
Hyun Ki YOON
;
Heung Kyu KO
Author Information
1. Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea. m1fenew@daum.net
- Publication Type:Original Article ; Evaluation Studies
- Keywords:
HCC;
TACE;
Infiltrative;
Survival
- MeSH:
Adult;
Aged;
Carcinoma, Hepatocellular/mortality/pathology/*therapy;
Chemoembolization, Therapeutic/*adverse effects/methods/mortality;
Female;
Humans;
Kaplan-Meier Estimate;
Liver Neoplasms/mortality/pathology/*therapy;
Male;
Middle Aged;
Prognosis;
Retrospective Studies;
Survival Rate;
Tumor Burden;
Venous Thrombosis/etiology
- From:Korean Journal of Radiology
2014;15(4):464-471
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in patients with infiltrative hepatocellular carcinoma (HCC) and to identify the prognostic factors associated with patient survival. MATERIALS AND METHODS: Fifty two patients who underwent TACE for infiltrative HCC were evaluated between 2007 and 2010. The maximum diameter of the tumors ranged from 7 cm to 22 cm (median 15 cm). Of 46 infiltrative HCC patients with portal vein tumor thrombosis, 32 patients received adjuvant radiation therapy for portal vein tumor thrombosis after TACE. RESULTS: The tumor response by European Association for the Study of the Liver criteria was partial in 18%, stable in 47%, and progressive in 35% of the patients. The median survival time was 5.7 months (Kaplan-Meier analysis). The survival rates were 48% at six months, 25% at one year, and 12% at two years. In the multivariable Cox regression analysis, Child-Pugh class (p = 0.02), adjuvant radiotherapy (p = 0.003) and tumor response after TACE (p = 0.004) were significant factors associated with patient survival. Major complications occurred in nine patients. The major complication rate was significantly higher in patients with Child-Pugh B than in patients with Child-Pugh A (p = 0.049, chi2 test). CONCLUSION: Transcatheter arterial chemoembolization can be a safe treatment option in infiltrative HCC patients with Child Pugh class A. Child Pugh class A, radiotherapy for portal vein tumor thrombosis after TACE and tumor response are good prognostic factors for an increased survival after TACE in patients with infiltrative HCCs.
